Trials / Unknown
UnknownNCT04337463
ATG-008 Combined With Toripalimab in Advanced Solid Tumors
An Open, Dose-escalation and Expansion Study With a Dual TORC1/2 Inhibitor of ATG-008 Combined With PD-1 Antibody of Toripalimab in Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-arm study with dose-escalation and expansion phases to access ATG-008 combined with Toripalimab in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATG-008 | Tablet |
| DRUG | Toripalimab | IV infusion |
Timeline
- Start date
- 2020-04-23
- Primary completion
- 2022-05-01
- Completion
- 2022-12-01
- First posted
- 2020-04-07
- Last updated
- 2021-05-17
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04337463. Inclusion in this directory is not an endorsement.